Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2017
Summary
GlobalData's clinical trial report, “Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profile Snapshots 33
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Source 58
List of Tables
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 11
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, G7 Countries (%), 2017* 16
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, E7 Countries (%), 2017* 20
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
List of Figures
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 11
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, G7 Countries (%), 2017* 15
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) to Hormonal Disorders Clinical Trials, E7 Countries (%), 2017* 19
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
GlobalData Methodology 57
